DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

Trinity Biotech plc (TRIB), a leading developer of diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market, has seen its stock price touch a 52-week low, ...

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

The company received substantial additional orders for TrinScreen HIV ... (down 25% from 3Q... Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval ...

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes ...

DUBLIN, Ireland - Trinity Biotech plc (NASDAQ:TRIB), a leading provider of diagnostic solutions for the healthcare industry, today announced the continuation of U.S. government funding for its HIV ...

Trinity Biotech’s redesigned ergonomic modular device features a reusable applicator and a rechargeable wearable transmitter that eliminates costly disposable components while delivering a ...

Shares of Trinity Biotech (NASDAQ:TRIB ... Based on data from 30 diabetic patients, Trinity (NASDAQ:TRIB) said its CGM device outperformed earlier Waveform CGM sensors, indicating a 25%–30% ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...